Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hikma Pharmaceuticals ( (GB:HIK) ) has provided an announcement.
Hikma Pharmaceuticals announced a leadership change with CEO Riad Mishlawi stepping down, and Executive Chairman Said Darwazah assuming CEO responsibilities. Khalid Nabilsi, the CFO, joins the Board to enhance strategic focus. The Board is confident in future growth under Said’s leadership, and a new CEO search will commence. The company’s 2025 guidance remains unchanged, with full-year results expected in February 2026.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £1793.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on GB:HIK Stock
According to Spark, TipRanks’ AI Analyst, GB:HIK is a Outperform.
Hikma Pharmaceuticals’ overall stock score is driven by strong financial performance and attractive valuation. While technical indicators suggest a bearish trend, the company’s strategic achievements and executive confidence provide a positive outlook. Earnings call insights and corporate events further support the stock’s potential for growth.
To see Spark’s full report on GB:HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC is a global company headquartered in the UK, specializing in creating high-quality medicines, both branded and non-branded generics. With over 45 years of experience, Hikma operates across North America, the Middle East and North Africa, and Europe, focusing on making medicines accessible to millions worldwide. The company is a leading licensing partner and invests in innovative health technologies through its venture capital arm.
Average Trading Volume: 725,092
Technical Sentiment Signal: Sell
Current Market Cap: £3.34B
See more data about HIK stock on TipRanks’ Stock Analysis page.